MX2012005597A - Formas cristalinas de pirazolopirimidinas sustituidas. - Google Patents

Formas cristalinas de pirazolopirimidinas sustituidas.

Info

Publication number
MX2012005597A
MX2012005597A MX2012005597A MX2012005597A MX2012005597A MX 2012005597 A MX2012005597 A MX 2012005597A MX 2012005597 A MX2012005597 A MX 2012005597A MX 2012005597 A MX2012005597 A MX 2012005597A MX 2012005597 A MX2012005597 A MX 2012005597A
Authority
MX
Mexico
Prior art keywords
acid
crystalline forms
pyrazolopyrimidines
crystal former
disorders
Prior art date
Application number
MX2012005597A
Other languages
English (en)
Inventor
Peter Boderke
Patrick Plitt
Bernhard Hauptmeier
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of MX2012005597A publication Critical patent/MX2012005597A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con cristales mixtos novedosos de pirazolopirimidinas y un formador de cristal mixto, en donde el formador de cristal mixto es un ácido carboxílico orgánico, preferentemente se selecciona del grupo de ácido gentísico, ácido succínico, y ácido xinafóico. Las pirazolopirimidinas, y en particular el compuesto A son potentes moduladores de mGluR5 y son útiles para la prevención y tratamiento de trastornos neurológicos agudos y crónicos, en particular trastornos del CNS (sistema nervioso central), que involucra excesiva excitación inducida por glutamato.
MX2012005597A 2009-11-25 2010-11-24 Formas cristalinas de pirazolopirimidinas sustituidas. MX2012005597A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26426909P 2009-11-25 2009-11-25
EP09177036 2009-11-25
PCT/EP2010/068093 WO2011064237A1 (en) 2009-11-25 2010-11-24 Crystalline forms of substituted pyrazolopyrimidines

Publications (1)

Publication Number Publication Date
MX2012005597A true MX2012005597A (es) 2012-05-29

Family

ID=42145278

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012005597A MX2012005597A (es) 2009-11-25 2010-11-24 Formas cristalinas de pirazolopirimidinas sustituidas.

Country Status (13)

Country Link
US (1) US20120283274A1 (es)
EP (1) EP2504340A1 (es)
JP (1) JP2013512216A (es)
KR (1) KR20120098745A (es)
CN (1) CN102695709A (es)
AR (1) AR079143A1 (es)
AU (1) AU2010323209A1 (es)
CA (1) CA2776361A1 (es)
IL (1) IL218717A0 (es)
MX (1) MX2012005597A (es)
RU (1) RU2012126150A (es)
WO (1) WO2011064237A1 (es)
ZA (1) ZA201202097B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013087815A1 (en) 2011-12-15 2013-06-20 Merz Pharma Gmbh & Co. Kgaa Liquid pharmaceutical composition containing a pyrazolopyrimidine derivative and pharmaceutical uses thereof
WO2013087808A1 (en) 2011-12-15 2013-06-20 Merz Pharma Gmbh & Co. Kgaa Pharmaceutical composition comprising a pyrazolopyrimidme and cyclodextrin
BR112015019276A2 (pt) 2013-02-19 2017-07-18 Pfizer compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
DK3177624T3 (da) 2014-08-06 2019-07-01 Pfizer Imidazopyridazinforbindelser

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007280428B2 (en) 2006-08-04 2012-04-12 Merz Pharma Gmbh & Co. Kgaa Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine
ES2359447T3 (es) * 2006-08-04 2011-05-23 MERZ PHARMA GMBH & CO. KGAA Pirazolopirimidinas sustituidas, un proceso para su preparación y su uso como medicina.
EP2090576A1 (en) * 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
EP2085398A1 (en) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine

Also Published As

Publication number Publication date
IL218717A0 (en) 2012-06-28
CA2776361A1 (en) 2011-06-03
EP2504340A1 (en) 2012-10-03
AU2010323209A1 (en) 2012-06-14
AR079143A1 (es) 2011-12-28
WO2011064237A1 (en) 2011-06-03
US20120283274A1 (en) 2012-11-08
KR20120098745A (ko) 2012-09-05
RU2012126150A (ru) 2013-12-27
CN102695709A (zh) 2012-09-26
JP2013512216A (ja) 2013-04-11
ZA201202097B (en) 2012-11-28

Similar Documents

Publication Publication Date Title
UA106692C2 (uk) ІМІДАЗО[5,1-f][1,2,4]ТРИАЗИНИ ДЛЯ ЛІКУВАННЯ НЕВРОЛОГІЧНИХ РОЗЛАДІВ
WO2012042539A3 (en) 3 -azabicyclo [3.1.0] hexane compounds useful for the treatment of cns disorders
IN2014KN00929A (es)
EA201500175A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
MX2012005597A (es) Formas cristalinas de pirazolopirimidinas sustituidas.
SG178997A1 (en) Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof
WO2014152536A3 (en) Inhibitors of leukotriene a4 hydrolase
CU24083B1 (es) Derivados de oxazina útiles como inhibidores de bace para el tratamiento de trastornos neurológicos
WO2007081857A3 (en) Cycloalkylamines as monoamine reuptake inhibitors
NO20100078L (no) (2S,3R)-N-(2-((3-pyridinyl)metyl)-1-azabicyklo[2.2.2]oct-3-yl)benzofuran-2-karboksamid, nye saltformer og deres anvendelse
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
TN2015000018A1 (en) 5-ht3 receptor antagonists
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
WO2012116050A3 (en) Phosphorus containing compounds as protein kinase inhibitors
TW200800958A (en) N-substituted-azacyclylamines as histamine-3 antagonists
MX2010002899A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3.
EA201001481A1 (ru) Производные третичного амина в качестве ингибиторов фосфодиэстеразы-4
WO2009118765A3 (en) Novel monoamine re-uptake inhibitor
EA201171393A1 (ru) 7-([1,2,4]ТРИАЗОЛО[1,5α]ПИРИДИН-6-ИЛ)-4-(3,4-ДИХЛОРФЕНИЛ)-1,2,3,4-ТЕТРАГИДРОИЗОХИНОЛИН И ЕГО ПРИМЕНЕНИЕ
MX2012010084A (es) Compuestos utiles para tratar transtornos neurodegenerativos.
MY159040A (en) Compounds
EA201300389A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
MX2015013059A (es) Sales, co-cristales, y polimorfos de un compuesto ansiolitico.
WO2007013936A3 (en) Method for treating nervous system disorders and conditions
EA201270610A1 (ru) Хинуклидиновые соединения как альфа-7 лиганды ацетилхолинового рецептора

Legal Events

Date Code Title Description
FA Abandonment or withdrawal